A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: Results of a multicenter clinical trial;Moxifloxacino frente a amoxicilina en el tratamiento de la neumonía adquirida en la comunidad en América Latina. Resultados de un ensayo clínico multicéntrico

Archivos de Bronconeumologia

Volumn 39, Issue 9, 2003, Pages 387-393

  Jardim, J R ^a   Rico, G ^b   De la Roza, C ^c   Obispo, E ^d   Urueta, J ^e   Wolff, M ^f   Miravitlles, M ^c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c HOSPITAL CLÍNIC   (Spain)

^d Hospital General de Tijuana   (Mexico)

^e INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^f Fundación Arriarán   (Chile)

Author keywords

Antibiotics; Pneumococcus; Pneumonia; Resistance; Treatment

Indexed keywords

AMOXICILLIN; MOXIFLOXACIN; PENICILLIN G;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM EXAMINATION; CENTRAL AMERICA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE TYPE A; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; MYCOBACTERIUM; NAUSEA; POPULATION RESEARCH; PREVALENCE; SIDE EFFECT; SOUTH AMERICA; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VOMITING;

EID: 0041692462     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13050627     Document Type: Article

References (43)

1. Macfarlane J. An overview of community-acquired pneumonia with lessons learned from the British Thoracic Society study. Semin Respir Infect 1994;9:153-65.
2. Marrie TJ. Community-acquired pneumonia. Clin Infect Dis 1994; 18:501-5.
3. Almirall J, Morato I, Riera F, Verdaguer A, Priu R, Coll P, et al. Incidence of community-acquired pneumonia and Chlamydia pneumoniae infection: a prospective multicentre study. Eur Respir J 1993;6:14-8.
4. Almirall J, Bolibar I, Vidal J, Sauca G, Coll P, Niklasson B, et al. Epidemiology of community-adquired pneumonia in adults: a population-based study. Eur Resp J 2000;15:157-63.
5. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730-54.
6. British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults. Thorax 2001;56(Suppl 4):1-64.
7. Mandell LA, Marrie TJ, Grossman RF, Chow AV, Hyland RH, the Canadian Community-Acquired Pneumonia Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000;31:383-412.
8. Grupo de Trabajo de la Asociación Latinoamericana del Tórax (ALAT). Recomendaciones ALAT sobre neumonía adquirida en la comunidad. Arch Bronconeumol 2001;37:340-8.
9. Rocha RT, Vital AC, Silva COS, Pereira CAC, Nakatani J. Pneumonia adquirida na comunidade em pacientes tratados ambulatorialmente: aspectos epidemiológicos, clínicos e radiológicos das pneumonías atípicas e não atípicas. J Pneumol 2000;26:5-14.
10. Luna CM, Famiglietti A, Absi R, Videla AJ, Nogueira FJ, Fuenzalida AD, et al. Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina. Chest 2000;118:1344-54.
11. Guzmán-Blanco M, Casellas JM, Sader HS. Bacterial resistance to antimicrobial agents in Latin America. The giant is awakening. Infect Dis Clin North Am 2000;14:67-81.
12. Petitpretz P, Arvis P, Marel M, Moita J, Urueta J. CAP5 Moxifloxacin Study Group. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001;119:185-95.
13. Barlett JG, Breiman RF, Mandell LA. Guidelines from the Infections Diseases Society of America: community-acquired pneumonia in adults; guidelines for management. Clin Infect Dis 1998;26:811-38.
14. Bohte R, Hermans J. Early recognition of Streptococcus pneumoniae in patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1996;15:201-5.
15. Performance standards for antimicrobial susceptibility testing; twelfth informational supplement. NCCLS 2002;22.
16. Appelbaum PC. Antimicrobial resistance in S. pneumoniae: an overview. Clin Infect Dis 1992;15:77-83.
17. Baquero F. Pneumococcal resistance to beta-lactam antibiotics: a global geographic overview. Microb Drug Resist 1995;1:115-20.
18. Geslin P, Buu-Hoy A, Fremaux A. Antimicrobial resistance in Streptococcus pneumoniae: an epidemiological survey in France 1970-1990. Clin Infect Dis 1992;15:95-8.
19. Bedos JP, Chevret S, Chastang C, Geslin P, Regnier B. Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with disminished susceptibility to penicillin: findings of a French survey. Clin Infect Dis 1996;22:63-72.
20. Pallares R, Gudiol F, Linares J, Ariza J, Rufi G, Murgui L, et al. Risk factors and response to antibiotic therapy in adults with bacterial pneumonia caused by penicillin-resistant pneumococci. N Engl J Med 1987;317:18-22.
21. Fenoll A, Martin Bourgon C, Muñoz R, Vicioso D, Casal J. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989. Rev Infect Dis 1991;13:56-60.
22. Garcfa-Leoni ME, Cercenado E, Rodeno P, Bernaldo de Quiros JC, Martínez-Hernández D, Bouza E. Susceptibility of Streptococcus pneumoniae to penicillin: a prospective microbiological and clinical study. Clin Infect Dis 1992;14:427-35.
23. Linares J, Pallares R, Alonso T, Perez JL, Ayats J, Gudiol F, et al. Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990). Clin Infect Dis 1992;15:99-105.
24. Pallares R, Linares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995;333:474-80.
25. Clavo-Sánchez AJ, Girón-González JA, López-Prieto D, Canueto-Quintero J, Sánchez-Porto A, Vergara-Campos A, et al. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 1997;24:1052-9.
26. Felmingham D, Gruneberg RN. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000;45:191-203.
27. Bauer T, Ewig S, Marcos MA, Schultze-Werninghaus G, Torres A. Streptococcus pneumoniae in community-acquired pneumonia. How important is drug resistance? Med Clin North Am 2001;85: 1367-79.
28. Wise R, Honeybourne D. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Eur Respir J 1999;14:221-9.
29. Miravitlles M. Moxifloxacin: an antibiotic designed for use in the community. Eur Respir Rev 2000;10:161-9.
30. Research Committee of the British Thoracic Society and the Public Health Laboratory Service. Community acquired pneumonia in adults in British hospitals in 1982-1983; a survey of etiology, mortality, prognostic factors and outcome. Q J Med 1987;62:195-220.
31. Blanquer J, Blanquer R, Borrás R, Nauffal D, Morales P, Menéndez R, et al. Aetiology of community acquired pneumonia in Valencia, Spain: a multicentre prospective study. Thorax 1991;46: 508-11.
32. Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 1989;11:586-99.
33. Feldman C, Ross S, Mahomed AG, Omar J, Smith C. The aetiology of severe community-acquired pneumonia and its impact on initial, empiric, antimicrobial chemotherapy. Respir Med 1995; 89:187-92.
34. Melbye H, Berdal BP, Straume B, Russell H, Vorland L, Thacker WL. Pneumonia: a clinical or radiographic diagnosis? Etiology and clinical features of lower respiratory tract infection in adults in general practice. Scand J Infect Dis 1992;24:647-55.
35. Almirall J, Mesalles E, Klamburg J, Parra O, Agudo A. Prognostic factors of pneumonia requiring admission to the intensive care unit. Chest 1995;107:511-6.
36. Menéndez R, Córdoba J, De la Cuadra P, Cremades MJ, López-Hontagas JL, Salavert M, et al. Value of the polymerase chain reaction assay in noninvasive respiratory samples for diagnosis of community-acquired pneumonia. Am J Respir Crit Care Med 1999;159:1868-73.
37. Ruiz-González A, Falguera M, Nogués A, Rubio-Caballero M. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med 1999;106:385-90.
38. Sopena N, Sabria-Leal M, Pedro-Botet ML, Padilla E, Domínguez J, Morera J, et al. Comparative study of the clinical presentation of Legionella pneumonia and other community-acquired pneumonias. Chest 1998;113:1195-200.
39. Lieberman D, Schlaeffer F, Boldur I, Lieberman D, Horowitz S, Friedman MG, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996;51:179-84.
40. Gleason PP, Kapoor WN, Stone RA, Lave JR, Obrosky DS, Schulz R, et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA 1997;278:32-9.
41. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999;159:2562-72.
42. Stahl JE, Barza M, DesJardin J, Martin R, Eckman MH. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999;159:2576-80.
43. Blondeau JM, Felmingham D. In vitro and in vivo activity of moxifloxacin against community respiratory tract pathogens. Clin Drug Invest 1999;18:57-8.